Pindolol (LB 46)

A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)

Also Known As:

Networked: 652 relevant articles (55 outcomes, 97 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Jones, N S: 2 articles (09/2013 - 06/2013)
2.	Muscat, R: 2 articles (09/2013 - 06/2013)
3.	Agius, A M: 2 articles (09/2013 - 06/2013)
4.	Kavasmaa, Tomi: 2 articles (01/2013 - 08/2009)
5.	Acharya, Ganesh: 2 articles (01/2013 - 08/2009)
6.	Mäkikallio, Kaarin: 2 articles (01/2013 - 08/2009)
7.	Erkinaro, Tiina: 2 articles (01/2013 - 08/2009)
8.	Haapsamo, Mervi: 2 articles (01/2013 - 08/2009)
9.	Räsänen, Juha: 2 articles (01/2013 - 08/2009)
10.	Zangrossi, Hélio: 2 articles (05/2011 - 09/2010)

Related Diseases

1.	Hypertension (High Blood Pressure) 11/01/1978 - "[Efficacy of single-daily-dose pindolol in arterial hypertension]." 04/01/1977 - "The efficacy of single dose of pindolol in hypertension." 08/01/2002 - "Nine patients taking oral doses of 10 mg/12 h rac-pindolol as part of their treatment for hypertension in pregnancy were recruited for the study. " 06/05/1989 - "In an open study that was conducted in general practice, 22 patients with previously-untreated mild hypertension received an average daily dose of 11.7 mg of pindolol over a 50-week study period. " 01/01/1989 - "This is the first long-term study of pindolol in a population-based sample of men with newly diagnosed hypertension. "
2.	Angina Pectoris 10/01/1982 - "In a randomized, controlled study we found a significant decrease in pressure-rate (double) product and an improvement in exercise tolerance in patients with angina pectoris treated with pindolol. " 10/01/1982 - "However, when patients were observed in a long-term double-blind crossover study, pindolol treatment did not produce a significant improvement in angina pectoris or exercise tolerance over placebo. " 05/01/1982 - "Investigations in small numbers of patients with angina pectoris have reported variable but generally beneficial results with pindolol." 10/01/1982 - "Variability of response to beta receptor blockade for angina pectoris in clinical trials: a study of pindolol." 01/01/1973 - "A double blind trial of LB-46 in the treatment of angina pectoris."
3.	Tachycardia (Tachyarrhythmias) 07/01/1977 - "[Large dose of pindolol as an effective treatment of intractable ventricular tachyarrhythmia complicating post myocardial infarctectomy. " 08/01/1982 - "The frequency-regulating effect of pindolol dependent on the level of exercise that produced the tachycardia: tachycardia at rest responded more markedly to pindolol than exercise-induced tachycardia; tachycardia due to low-level exercise responded better than that due to higher level exercise. " 08/01/1982 - "A linear correlation exists between the logarithm of plasma concentrations of pindolol and cardiac beta-adrenoceptor blockade expressed as a reduction of exercise-induced tachycardia. " 01/01/1981 - "During treatment with pindolol 20 mg retard once daily, cardiac beta-adrenoceptor blockade, measured by the reduction in exercise-induced tachycardia and in the exercise-induced rise in systolic blood pressure, at almost all times throughout the 24 h period was at least as great as during treatment with pindolol 5 mg t. " 01/01/1980 - "A linear fall of the pharmacological effect (reduction of exercise-induced tachycardia) and an exponential fall of pindolol plasma levels were observed, indicating a linear relationship between the reduction of exercise-induced tachycardia and the logarithm of plasma concentration."
4.	Coronary Artery Disease (Coronary Atherosclerosis) 01/01/1989 - "Improvement in wall motion after pindolol: a mechanism for the preservation of left ventricular function in coronary artery disease." 11/01/1980 - "The effects of intravenous (0.4 mg) and oral pindolol (5 mg, t.i.d.) on exercise tolerance and electrocardiographic ST-segment changes were investigated in 20 patients with documented coronary artery disease (16 males and 4 females; mean age, 56.7 years). " 08/01/1982 - "Twelve patients with documented coronary arteriosclerosis and severe stable angina pectoris were treated with the beta blocker pindolol, 5 mg four times a day, utilizing a double-blind crossover protocol. " 05/01/1985 - "In summary, derivation of normalized regional LV ejection fraction values allows the demonstration of significant improvement in resting LV function with pindolol, but not with propranolol in patients with regional dysfunction due to coronary artery disease. " 01/01/1983 - "To determine whether the depression of left ventricular pumping activity associated with beta-blockade alone could be offset by a substantial degree of partial agonist activity, the haemodynamic dose-response effects of intravenous propranolol and pindolol were compared in a randomised between-group saline controlled study in twenty patients with angiographically proven coronary artery disease. "
5.	Vasovagal Syncope 10/01/1995 - "In conclusion, pindolol appears to be safe and effective as initial treatment for vasovagal syncope." 11/01/2004 - "This study evaluated the efficacy of pindolol, a noncardioselective beta blocker with intrinsic sympathetic activity, on neurocardiogenic syncope using a head-up tilt-table test in 66 patients. " 10/01/1995 - "Efficacy of pindolol for treatment of vasovagal syncope." 10/01/1995 - "The purpose of this study was to evaluate the efficacy, safety, and tolerance of pindolol as initial therapy for vasovagal syncope. " 11/01/2004 - "Usefulness of pindolol for treatment of neurocardiogenic syncope."

Related Drugs and Biologics

1.	Propranolol (Inderal)
2.	Verapamil (Calan)
3.	Serotonin (5 Hydroxytryptamine)
4.	Atenolol (Tenormin)
5.	Metoprolol (Lopressor)
6.	Fluoxetine (Prozac)
7.	Clopamide
8.	Labetalol (Normodyne)
9.	Alprenolol
10.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Bariatric Surgery
3.	Aftercare (After-Treatment)
4.	Sodium-Restricted Diet (Diet, Sodium Restricted)
5.	Oral Administration